CRISPR Therapeutics CRSP Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's return on equity?
- CRISPR Therapeutics (CRSP) reported return on equity of -31.2% in Q1 2026.
- How has CRISPR Therapeutics's return on equity changed year-over-year?
- CRISPR Therapeutics's return on equity decreased by 58.3% year-over-year, from -19.7% to -31.2%.
- What is the long-term trend for CRISPR Therapeutics's return on equity?
- Over 3 years (2020 to 2025), CRISPR Therapeutics's return on equity has grown at a 4.0% compound annual growth rate (CAGR), from -26.8% to -30.2%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.